Who is sponsoring NCT07206849?

NCT07206849 is sponsored by Nationwide Children's Hospital.

What drugs are being tested in NCT07206849?

Interventions in NCT07206849: Tovorafenib.

What condition does NCT07206849 study?

NCT07206849 studies High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Metastatic Brain Tumor.

Is NCT07206849 still recruiting?

NCT07206849 is currently not yet recruiting. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT07206849

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study of Tovorafenib in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor Alterations in the Mitogen-Activated Protein Kinase (MAPK) Pathway

Not yet recruiting Phase 2 Last updated 3 April 2026

What this trial tests

Phase 2 trial testing Tovorafenib in High Grade Glioma (HGG) of the Brain With BRAF Aberration in 79 participants. Not yet recruiting.

Timeline

1 May 2026

Primary endpoint
1 May 2030

1 May 2037

Quick facts

Lead sponsor	Nationwide Children's Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	79
Start date	1 May 2026
Primary completion	1 May 2030
Estimated completion	1 May 2037

Drugs / interventions tested

Tovorafenib (TOVORAFENIB) — full drug profile →

Conditions studied

High Grade Glioma (HGG) of the Brain With BRAF Aberration — all drugs for High Grade Glioma (HGG) of the Brain With BRAF Aberration →
High Grade Glioma (III or IV) — all drugs for High Grade Glioma (III or IV) →
Diffuse Intrinsic Pontine Glioma — all drugs for Diffuse Intrinsic Pontine Glioma →
High Grade Glioma — all drugs for High Grade Glioma →

Sponsor

Nationwide Children's Hospital

Who can join

Adults 12 Months to 39, any sex, with High Grade Glioma (HGG) of the Brain With BRAF Aberration or High Grade Glioma (III or IV). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Progression Free Survival Stratum A
Time frame: 6 years
Estimate the progression-free survival (PFS) distribution for pediatric and young adult patients (age: ≥12 months and ≤39 years) with newly-diagnosed BRAFV600 mutant HGG (Stratum A) who receive tovorafenib monotherapy post RT compared to molecularly-stratified, matched historical controls.

Sponsor's own description

The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted therapies in pediatric oncology: A start.
Shah N. · · 2026 · PMID 41994561 · DOI 10.1016/j.omton.2026.201146

Verify or expand the search:

Other trials of Tovorafenib

Trials testing the same drug.

NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting
NCT05828069 — A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histioc · Phase 2 · recruiting
NCT06381570 — Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Glioma · EARLY_PHASE1 · recruiting
NCT05465174 — Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults · Phase 2 · recruiting

Other recruiting trials for High Grade Glioma (HGG) of the Brain With BRAF Aberration

Currently open trials in the same condition.

NCT04201457 — A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration · Phase 1, PHASE2 · active not recruiting

Other Nationwide Children's Hospital trials

Trials by the same sponsor.

NCT07435792 — TetraGraph to Evaluate Onset and Recovery Times of Rocuronium · NA · not yet recruiting
NCT07026942 — Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML · Phase 1, PHASE2 · not yet recruiting
NCT06795126 — Little NIRVANA for Pediatric Pain and Anxiety · NA · enrolling by invitation
NCT06854991 — Healthy Children and Virtual Reality Mediation of Simulated Pain · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07206849 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nationwide Children's Hospital
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07206849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing